AVEO

ANALYST NOTE: AVEO PHARMACEUTICALS, INC. DATE: 2026-06-13 SUBJECT: Structural Setup & Business Fundamentals Review

1. Structural Readiness

State: Context-Only Conservative Entry: — Current Price: $15.00 Extension: — ATR at Breakout: — ATR Current: 0.2% (Sub-threshold) Pivot Strength: — Cap Bucket: Mid Sector: — Industry: —

Structural Assessment:

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Exposure: None Named

At this date, AVEO is not associated with a named secular macro thesis. The investment case is strictly tactical and setup-led. There is no evidence of a broader thematic tailwind (e.g., a specific regulatory shift or demographic shift) being actively priced in as a primary driver. The conviction must be derived entirely from the quality of the technical setup (which is currently absent) and the underlying business fundamentals. No macro thesis should be invented to support the position; the name is judged on its operational execution and structural readiness alone.

3. Business Fundamentals

Company Profile: AVEO Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the development and commercialization of therapeutic solutions for cancer patients. Its primary commercial product is FOTIVDA (tivozanib), an oral, once-daily vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor approved for the treatment of renal cell carcinoma (RCC).

Business Model & Evidence (PIT as of 2026-06-13):

• Commercial Product (FOTIVDA): The company maintains a network of collaborations to support its commercialization efforts. As of the latest available profile data (2026-06-12), AVEO partners with entities including CANbridge Life Sciences Ltd., EUSA Pharma (UK) Limited, Novartis International Pharmaceutical Ltd., Biodesix, Inc., St. Vincent's Hospital Sydney Limited, Biogen Idec International GmbH, Kyowa Kirin Co., Ltd., and AstraZeneca PLC.
• Pipeline Assets: The pipeline includes AV-380 (a Phase-1b candidate in GDF15 expressing cancer patients) and Ficlatuzumab (a monoclonal antibody targeting hepatocyte growth factor).
• Historical Performance Context: While the current date is 2026, the most recent detailed earnings transcript evidence available (dated 2022-08-04) provides the baseline for the company's commercial trajectory and management expectations.
• Revenue Guidance: Management previously guided for $100 million to $110 million in FOTIVDA US net product revenue for fiscal year 2022.
• Prescription Growth: In Q2 of that reporting period, the company recorded 1,157 commercial prescriptions, representing an 18% increase over Q1 and a 309% increase year-over-year.
• Clinical Positioning: FOTIVDA was noted as the only treatment with a Category 1 recommendation for RCC patients who have received two or more prior therapies.
• Strategic Intent: Management expressed confidence in the drug fulfilling an unmet need for patients relapsed or refractory to two or more prior therapies.

Note on Evidence Gap: The provided evidence block contains no financial data, earnings transcripts, or clinical trial updates specifically dated between 2023 and 2026. The 2022 transcript data represents the last confirmed operational baseline. There is no PIT evidence in the provided text confirming the status of the "fully enrolled" trial mentioned for Q2 2023 or the subsequent FDA discussions regarding tivozanib in combination with nivolumab.

4. Archetype and Conviction

Archetype Candidate: Quality Compounder (Source: Layer A) Fit Analysis: The classification as a "Quality Compounder" is based on the company's historical positioning as a specialized oncology developer with a Category 1 approved therapy and a robust partnership network. However, the "Quality Compounder" label requires sustained execution and revenue growth, which cannot be verified with the current evidence gap (2023–2026).

Conviction Stack:

• Thesis Strength: Low. No named secular thesis; purely tactical.
• Evidence Quality: Mixed. Strong historical data (2022) regarding prescription growth and Category 1 status, but a complete lack of recent (2023–2026) operational data.
• Structural Quality: Weak. The current ATR of 0.2% is sub-threshold, and no structural setup (Coil) is present.
• Rerating Potential: Unknown. Without recent clinical data or updated financial guidance, the market's view on the company's growth trajectory is undefined.

Valuation Context: No valuation metrics (P/E, P/S, Market Cap) are provided in the evidence block for the 2026 date. The "Mid" cap bucket classification is noted, but without earnings or revenue figures for 2026, a valuation assessment cannot be performed.

5. Invalidations, Strengths, and Gaps

What Would Invalidate the Case:

• Fundamental: If recent clinical trials (post-2022) fail to meet endpoints or if the partnership network dissolves without replacement.
• Financial: If revenue guidance for 2026 falls significantly below the 2022 trajectory ($100M+), indicating a loss of commercial traction.

What Would Strengthen the Case:

• Structural: Formation of a high-quality Coil with a breakout above a defined resistance level and ATR expanding into the 4–6% range.
• Fundamental: Confirmation of successful enrollment and positive data readouts for the tivozanib/nivolumab combination trial (previously targeted for 2023).
• Strategic: Announcement of a new major strategic partner or funding deal to support registration trials.

Honest Gaps in Evidence Base:

• Critical Missing Data: There is no evidence provided for the period 2023 through 2026. The 2022 earnings transcript is the only operational data point.
• Missing Financials: No 2026 revenue, cash burn, or balance sheet data is available.
• Missing Clinical Status: The status of the "fully enrolled" trial mentioned for Q2 2023 is unknown.
• Missing Technicals: No price history, volume data, or volatility metrics (other than the current 0.2% ATR) are available to construct a technical setup.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: low Key evidence: Current price is $15; ATR is 0.2% (sub-threshold); No technical setup (Coil) is formed; No financial data available for 2023-2026. Key risks: Complete lack of recent operational data; Potential failure of clinical trials mentioned in 2022 guidance; Low volatility suggests lack of institutional interest or liquidity. Sizing hint: Position size should be zero or negligible until a structural setup forms and recent financials are verified. Expected path: The stock will likely remain in a low-volatility consolidation range until a catalyst (clinical data or partnership) triggers a structural move. Expected horizon: Indefinite until a new setup forms or evidence is released. Failure mode to watch: A sustained period of low volume and price stagnation combined with the absence of any corporate announcements, indicating a lack of market relevance.